Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Myelodysplastic Syndromes 142Leukemia, Lymphocytic, Chronic, B-Cell 139Leukemia 127Multiple Myeloma 117Lymphoma 115Lymphoma, Non-Hodgkin 112Recurrence 78Hematologic Neoplasms 74Melanoma 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Hodgkin Disease 67Lymphoma, B-Cell 61Lymphoma, Mantle-Cell 51Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Burkitt Lymphoma 41Ovarian Neoplasms 39Neoplasms 39Myeloproliferative Disorders 39Neoplasm Metastasis 33Lymphoma, B-Cell, Marginal Zone 30Graft vs Host Disease 29Neoplasms, Plasma Cell 28Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 27Leukemia, Biphenotypic, Acute 25Primary Myelofibrosis 24Anemia, Refractory, with Excess of Blasts 23

Interventions

fludarabine 2Cyclophosphamide 2Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Myositis × fludarabine × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT04561557 2024-10-30

CARTinNS

Tongji Hospital

Phase EARLY_PHASE1 Recruiting
36 enrolled
Plasma cell

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Autoimmune Diseases, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, POEMS Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡